Penumbra Inc Revenue Growth Rates (PEN), Current and Historic Growth - CSIMarket
CSIMarket
 


Penumbra Inc  (NYSE: PEN)
 

PEN's Revenue Growth by Quarter and Year

Penumbra Inc's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PEN/growth
https://api.csimarket.com/api/v1/companies/PEN/fundamentals
https://api.csimarket.com/api/v1/companies/PEN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
PEN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 410.15
2nd Quarter June 390.05
1st Quarter March 374.76
FY 1,174.96

PENs Annual Revenue
Penumbra Inc's Revenue in the fiscal year 2025 $ 1,403.67 millions
Penumbra Inc's Revenue in the fiscal year 2024 $ 1,194.62 millions
Penumbra Inc's Revenue in the fiscal year 2023 $ 1,058.52 millions
Penumbra Inc's Revenue in the fiscal year 2022 $ 847.13 millions
Penumbra Inc's Revenue in the fiscal year 2021 $ 747.59 millions




PEN Revenue third quarter 2026 Y/Y Growth Comment
Penumbra Inc reported Revenue increase of 15.63% year on year in the third quarter 2026, to $ 410.15 millions, this is lower than Penumbra Inc's recent average Revenue improvement of 24.3%.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 122 other companies have achieved higher Revenue growth. While Penumbra Inc' s Revenue growth of 15.63% ranks overall at the positon no. 2277 in the third quarter 2026.




PEN Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 15.63 %
2nd Quarter June 14.9 %
1st Quarter March 15.62 %
FY   -

Financial Statements
Penumbra Inc's third quarter 2026 Revenue $ 410.15 millions PEN's Income Statement
Penumbra Inc's third quarter 2025 Revenue $ 354.69 millions Quarterly PEN's Income Statement


PEN Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 5.15 %
2nd Quarter June 4.08 %
1st Quarter March -2.76 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #123
Healthcare Sector #331
Overall #2277

Revenue Y/Y Growth Statistics
High Average Low
52.79 % 24.3 % 2.38 %
(Jun 30 2016)  
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #123
Healthcare Sector #331
Overall #2277
Revenue Y/Y Growth Statistics
High Average Low
52.79 % 24.3 % 2.38 %
(Jun 30 2016)  

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Penumbra Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.99 % -23.46 %
(Sep 30 2020)  


PEN's III. Quarter Q/Q Revenue Comment
Penumbra Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.15% quarter on quarter, to $ 410.15 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 4.49% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1237.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #51
Healthcare Sector #180
Overall #1237
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #51
Healthcare Sector #180
Overall #1237
Revenue Q/Q Growth Statistics
High Average Low
43.73 % 5.99 % -23.46 %
(Sep 30 2020)  


PEN's III. Quarter Q/Q Revenue Comment
Penumbra Inc achieved in the III. Quarter 2026 below company average Revenue increase of 5.15% quarter on quarter, to $ 410.15 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 4.49% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 50 other companies have achieved higher Revenue quarter on quarter growth. While Penumbra Inc's Revenue growth quarter on quarter, overall rank is 1237.


Penumbra Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,560.33
Y / Y Revenue Growth (TTM) 16.98 %
Year on Year Revenue Growth Overall Ranking # 1247
Seqeuential Revenue Change (TTM) 3.69 %
Seq. Revenue Growth (TTM) Overall Ranking # 2277


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Penumbra Inc's cumulative twelve months Revenue were $ 1,560 millions, company would post below average annual Revenue growth of 3.69% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Penumbra Inc's Revenue growth from the 390.05% growth in Jun 30 2026.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 983 to 1247.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 123
Healthcare Sector # 222
Overall # 1247

Revenue TTM Y/Y Growth Statistics
High Average Low
52.79 %
24.3 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 331
S&P 500 # 2277
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Penumbra Inc's cumulative twelve months Revenue were $ 1,560 millions, company would post below average annual Revenue growth of 2.38% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Penumbra Inc's Revenue growth from the 390.05% growth in Jun 30 2026.

In the Healthcare sector 221 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 983 to 1247.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 123
Healthcare Sector # 222
Overall # 1247

Revenue TTM Y/Y Growth Statistics
High Average Low
52.79 %
24.3 %
2.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 331
S&P 500 # 2277




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
PEN's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vericel Corporation26.47%$ 26.470 millions
Axogen inc 26.22%$ 26.218 millions
Cardio Diagnostics Holdings Inc 25.74%$ 25.744 millions
Edap Tms Sa25.55%$ 25.549 millions
Lifestance Health Group Inc 25.30%$ 25.303 millions
Rockwell Medical inc 25.21%$ 25.210 millions
Intelligent Bio Solutions Inc 25.19%$ 25.188 millions
The Oncology Institute Inc 24.31%$ 24.313 millions
Vanda Pharmaceuticals Inc 24.10%$ 24.098 millions
Mannkind Corporation24.04%$ 24.035 millions
Castle Biosciences Inc 23.90%$ 23.901 millions
Coherus Oncology inc 23.36%$ 23.360 millions
Prestige Consumer Healthcare Inc 22.93%$ 22.929 millions
Acadia Pharmaceuticals Inc 22.85%$ 22.847 millions
Protalix Biotherapeutics inc 22.82%$ 22.822 millions
Capsovision Inc 22.44%$ 22.443 millions
Veracyte Inc 22.10%$ 22.105 millions
Radnet Inc 22.07%$ 22.068 millions
Alkermes Plc 21.80%$ 21.804 millions
Alpha Teknova Inc 21.52%$ 21.523 millions
Anteris Technologies Global Corp 20.98%$ 20.979 millions
Trisalus Life Sciences Inc 20.81%$ 20.807 millions
Orthopediatrics Corp20.55%$ 20.551 millions
Alpha Pro Tech Ltd 19.73%$ 19.729 millions
Insulet Corporation19.21%$ 19.213 millions
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Outset Medical Inc 17.51%$ 17.510 millions


About Penumbra Inc Revenue Growth Rates (PEN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Penumbra Inc (CIK 1321732).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001321732-26-000043
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Penumbra Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.